Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpress...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Pharmaceuticals (Basel)
Hoofdauteurs: Ferrer-Font, Laura, Villamañan, Lucia, Arias-Ramos, Nuria, Vilardell, Jordi, Plana, Maria, Ruzzene, Maria, Pinna, Lorenzo A., Itarte, Emilio, Arús, Carles, Candiota, Ana Paula
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5374428/
https://ncbi.nlm.nih.gov/pubmed/28208677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph10010024
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items